IN BRIEF: Genus trial shows gene edited pigs resistant to PRRS virus
IN BRIEF: Genus trial shows gene edited pigs resistant to PRRS virus
Read moreThu, 14th Nov 2019 13:10
IN BRIEF: Genus trial shows gene edited pigs resistant to PRRS virus
Read more(Sharecast News) - Animal genetics company Genus provided an update on its porcine reproductive and respiratory syndrome virus resistance programme as part of its capital markets event on Tuesday.
Read moreDIRECTOR DEALINGS: Sealand Capital chair invests amid licence talks
Read moreLONDON MARKET MIDDAY: Biden spends big; Deliveroo dives on debut
Read moreBROKER RATINGS: BP cut by Morgan Stanley; Jefferies raises Hikma
Read moreIN BRIEF: Genus adds molecular biology head Jason Chin to board
Read moreDIRECTOR DEALINGS: Hochschild, Wizz Air, Clipper Logistics Execs Sell
Read moreLONDON MARKET CLOSE: Stocks Edge Lower As US Bond Yields Rise
Read more(Sharecast News) - Medica Group: Liberum initiates at buy with a target price of 200p.
Read moreLONDON MARKET MIDDAY: Stocks Notch Moderate Gains Ahead Of US Data
Read moreGenus Posts "Very Strong" Interim Results Despite Covid-19 Impact
Read moreBROKER RATINGS: AstraZeneca, Reckitt And Tesco Receive Upgrades
Read more(Sharecast News) - Animal genetics company Genus reported a record adjusted profit before tax in its interim results on Thursday, as revenue in its porcine genetics business 'PIC' rose 8%.
Read more